High Growth Tech Stocks in France to Watch This October 2024

As global markets experience fluctuations, with the pan-European STOXX Europe 600 Index seeing a modest rise amid potential ECB rate cuts and economic stimuli from China, France's CAC 40 Index also recorded a slight increase of 0.48%. In this dynamic environment, identifying high-growth tech stocks in France requires focusing on companies that demonstrate robust innovation capabilities and adaptability to shifting economic landscapes.

Top 10 High Growth Tech Companies In France

Name	Revenue Growth	Earnings Growth	Growth Rating
Icape Holding	17.24%	33.91%	★★★★★☆
Archos	25.98%	77.41%	★★★★★☆
Valneva	22.83%	17.91%	★★★★★☆
Munic	42.94%	174.09%	★★★★★☆
Oncodesign Société Anonyme	14.68%	101.18%	★★★★★☆
Adocia	70.20%	63.97%	★★★★★☆
Valbiotis	33.52%	39.79%	★★★★★☆
VusionGroup	28.35%	81.72%	★★★★★★
beaconsmind	26.32%	74.88%	★★★★★★
Pherecydes Pharma Société anonyme	63.30%	78.85%	★★★★★☆

Click here to see the full list of 40 stocks from our Euronext Paris High Growth Tech and AI Stocks screener.

Let's explore several standout options from the results in the screener.

Bolloré (ENXTPA:BOL)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Bolloré SE operates in transportation and logistics, communications, and industry sectors across multiple continents including Europe, the Americas, Asia, Oceania, and Africa with a market capitalization of €16.78 billion.

Operations: The company generates revenue primarily from its communications segment, contributing €14.86 billion, followed by Bolloré Energy at €2.75 billion and the industry sector at €353 million.

Bolloré SE, a French conglomerate, has demonstrated remarkable financial resilience and growth potential. In the first half of 2024, the company's sales soared to €10.59 billion from €6.23 billion in the previous year, reflecting a robust increase in revenue. This surge aligns with an anticipated annual revenue growth rate of 8.3%, outpacing the French market's average of 5.6%. Moreover, Bolloré's earnings are expected to skyrocket by 32.7% annually over the next three years, significantly exceeding the market forecast of 12.1%. Despite these impressive figures, it’s crucial to note that Bolloré’s forecasted Return on Equity stands at a modest 4.9%, suggesting potential challenges in achieving higher profitability relative to its equity base. The company recently affirmed its commitment to shareholder returns by maintaining its interim dividend at €0.02 per share despite substantial profit increases—net income escalated dramatically to €3.76 billion from just €114 million year-over-year as reported in their latest earnings announcement on July 30th, 2024. This decision underscores Bolloré's stable financial management and dedication to delivering consistent shareholder value amidst significant growth phases and sectoral shifts within high-growth tech environments in France.

• Click here and access our complete health analysis report to understand the dynamics of Bolloré.

• Explore historical data to track Bolloré's performance over time in our Past section.

Genfit (ENXTPA:GNFT)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Genfit S.A. is a late-stage biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions for metabolic and liver-related diseases, with a market capitalization of €272.95 million.

Operations: Genfit S.A. generates revenue primarily through its research and development of innovative medicines and diagnostic solutions, amounting to €80.47 million. The company's focus is on metabolic and liver-related diseases, leveraging its expertise in drug discovery and development.

Genfit S.A. has pivoted impressively, turning a net loss into a substantial profit within a year as evidenced by its latest half-year earnings report, showcasing net income of €30.31 million compared to a loss of €20.85 million previously. This turnaround is underscored by robust revenue growth of 17.8% annually, outperforming the French market's average growth rate of 5.6%. Notably, Genfit's commitment to innovation is evident in its R&D spending which remains substantial, aligning with its strategic focus on developing advanced biotech solutions that cater to unmet medical needs—a sector poised for significant expansion given global health trends and technological advancements in medicine.

• Navigate through the intricacies of Genfit with our comprehensive health report here.

• Assess Genfit's past performance with our detailed historical performance reports.

OVH Groupe (ENXTPA:OVH)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: OVH Groupe S.A. is a global provider of public and private cloud services, shared hosting, and dedicated server solutions with a market capitalization of approximately €1.29 billion.

Operations: OVH Groupe generates revenue primarily from its private cloud services, contributing €589.61 million, followed by public cloud at €169.01 million, and web cloud solutions at €185.43 million. The company's focus on diverse cloud offerings highlights its strategic emphasis on catering to a wide range of digital infrastructure needs globally.

OVH Groupe, amidst a volatile market, demonstrates potential with a projected revenue increase of 9.7% annually, outpacing the French market's average of 5.6%. Despite current unprofitability, the company is on a trajectory towards profitability with earnings expected to surge by 101.4% per year. This growth is underpinned by strategic R&D investments which are crucial for maintaining competitive edge in the rapidly evolving tech landscape. As OVH moves towards profitability within three years, its commitment to innovation and development positions it well within France's high-tech sector, signaling promising future prospects despite present challenges.

• Unlock comprehensive insights into our analysis of OVH Groupe stock in this health report.

• Understand OVH Groupe's track record by examining our Past report.

Where To Now?

• Reveal the 40 hidden gems among our Euronext Paris High Growth Tech and AI Stocks screener with a single click here.
• Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes.
• Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Seeking Other Investments?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com